News

All existing institutional investors participated in the financing, led by MPM Bio IV NVS Strategic Fund and including MPM Capital, The Wellcome Trust, HealthCare Ventures, Oxford Bioscience Partners,

Most recently, Dr Stark served as an executive director at Amgen, and COO at iZumi Bio. Dr Stark latest responsibilities include strategic operations within R&D, integration of mergers

This approval expands ImClone’s total available production volume capacity for its proprietary pipeline of novel antibodies, which are now entering late-stage clinical development. ImClone’s 250,000sqft multi-suite BB50 facility

In addition, there will be further price adjustments, a 1.9% cut in January 2010, not contingent on the growth of the drugs bill; plus increases of 0.1% in

Under the terms of the five-year agreement, Akorn will be responsible for the manufacturing and supply of the ophthalmic drug product. Akorn is the abbreviated new drug application

This part of the first clinical study investigated the ability of Sym001 to clear RhD-positive red blood cells given intravenously to 24 RhD-negative healthy males. Positive control was

GeneLink’s DNA assessments are based on GeneLink’s scientific research and patents and utilize GeneLink’s patented DNA Collection Kit. In August, 2008 GeneWize Life Sciences, a wholly owned subsidiary

Under the agreement, AstraZeneca will receive $253 million for the over-the-counter (OTC) brands, which include analgesics Alvedon and Reliv, Nezeril/Nasin for decongestion, Minifom for gastrointestinal disorder and Duroferon

Under the terms of the agreement, Omnicare Clinical Research’s clinical supplies division will provide Patheon’s customers with various clinical supply services that include monitoring, distribution and return accountability.